Serum thyroglobulin, its autoantibody and thyroid stimulating antibodies in the endocrine exophthalmos

1981 ◽  
Vol 96 (2) ◽  
pp. 192-198 ◽  
Author(s):  
Ulla Feldt Rasmussen ◽  
Axel Kemp ◽  
Karine Bech ◽  
Stig Nistrup Madsen ◽  
John Date

Abstract. Serum concentrations of thyroglobulin, its antibody, and thyroid stimulating antibodies were studied in 32 patients referred to a department of eye-diseases for exophthalmos. Twenty-three of the patients were or had been medically treated for Graves' disease, one had toxic nodular goitre, one subclinical myxoedema, three euthyroid exophthalmos and four were shown to have non-endocrine eye-disease. In patients with medically treated Graves' disease serum thyroglobulin was significantly elevated (P < 0.02), the still toxic patients accounting for the highest values. Both thyroid stimulating and thyroglobulin antibodies were detectable in 4 of 18 patients. The rest of the patients had normal concentrations of thyroglobulin and undetectable thyroid stimulating antibodies, but 3 patients had measurable thyroglobulin antibodies. In Graves' patients there was no correlation between serum concentrations of thyroid stimulating antibodies and thyroglobulin, and no clear difference between the frequency of thyroid stimulating or thyroglobulin antibodies in the patients with persistent elevation of circulating thyroid hormones and those remaining euthyroid. A relation between the thyroid autoantibodies, thyroglobulin and the thyroid hormonal level or severity of the exophthalmic state could not be demonstrated. It is suggested that hyperthyroidism and exophthalmos are separate disorders, and immunological phenomena probably involved in the pathogenesis of exophthalmos associated with Graves' disease appear to be reflected only locally.

2011 ◽  
Vol 14 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Franciszek Rogowski ◽  
Saeid Abdelrazek ◽  
Piotr Szumowski ◽  
Anna Zonenberg ◽  
Adam Parfienczyk ◽  
...  

2001 ◽  
Vol 28 (9) ◽  
pp. 1360-1364 ◽  
Author(s):  
C. Körber ◽  
P. Schneider ◽  
N. Körber-Hafner ◽  
H. Hänscheid ◽  
C. Reiners

Allergy ◽  
1982 ◽  
Vol 37 (3) ◽  
pp. 161-167 ◽  
Author(s):  
Ulla Feldt-Rasmussen ◽  
Karine Bech ◽  
John Date ◽  
Per Hyltoft Pedersen ◽  
Klaus Johansen ◽  
...  

1994 ◽  
Vol 40 (6) ◽  
pp. 803-806 ◽  
Author(s):  
Luca Chiovato ◽  
Ferruccio Santini ◽  
Paolo Vitti ◽  
Giovanna Bendinelli ◽  
Aldo Pinchera

2008 ◽  
Vol 158 (6) ◽  
pp. 823-827 ◽  
Author(s):  
Mirna Abraham-Nordling ◽  
Ove Törring ◽  
Mikael Lantz ◽  
Bengt Hallengren ◽  
Hans Ohrling ◽  
...  

ObjectivesTo investigate the incidence of hyperthyroidism in Stockholm County, in those patients who were diagnosed with hyperthyroidism for the first time during the years 2003–2005.DesignAll new cases of hyperthyroidism ≥18 years of age were prospectively registered to calculate the total incidence of hyperthyroidism, as well as the incidence of the subgroups: Graves' disease (GD), toxic multinodular goitre and solitary toxic adenoma (STA). Eight specialized units/hospitals in Stockholm County participated in the registration. The participating physicians were all specialists in medical endocrinology, oncology, nuclear medicine or surgery.ResultsDuring a 3-year period, 1431 new patients of hyperthyroidism were diagnosed in a well-defined adult population (>18 years of age) of in average 1 457 036 inhabitants. This corresponds to a mean annual incidence of hyperthyroidism of 32.7/100 000. The incidence of GD was 24.5/100 000 per year, toxic nodular goitre was 3.3/100 000 per year and STA was 4.9/100 000 per year.ConclusionsThe total incidence of hyperthyroidism in Stockholm County was found to be 32.7/100 000 per year, of which 75% had GD. There were a higher percentage of smokers among the patients with hyperthyroidism compared with the overall population in Stockholm, but no difference in the frequency of smoking between patients with GD and toxic nodular goitre.


2001 ◽  
Vol 55 (1) ◽  
pp. 15-19 ◽  
Author(s):  
A. Matos-Santos ◽  
E. Lacerda Nobre ◽  
J. Garcia E Costa ◽  
P. J. Nogueira ◽  
A. Macedo ◽  
...  

1967 ◽  
Vol 55 (3) ◽  
pp. 497-521 ◽  
Author(s):  
Brian R. Webster ◽  
Amy Britton ◽  
Robert Volpé ◽  
Calvin Ezrin

ABSTRACT The disappearance of an intravenously injected tracer dose of 131I-labelled L-thyroxine from the circulation has been followed for 70 minutes. We have confirmed that the most significant separation between euthyroid subjects and patients with hyperthyroidism or myxoedema is given by the single exponential slope of the regression of blood radioactivity occurring between 20 and 50 minutes after T4* injection. This slope is referred to as the acute T4* half-time. When there is no alteration in total TBG the acute T4* half-time is closely related to the plasma BEI concentration. Increase in the latter due to Graves' disease, toxic nodular goitre, or exogenous administration of thyroxine or desiccated thyroid, results in a comparable acceleration in the acute T4* half-time compared to the value in euthyroid control subjects. Conversely patients with a low BEI due to primary or radioactive iodine induced myxoedema all have a significantly slow acute T4* half-time compared to normal subjects. There was no specific abnormality in the handling of thyroxine by patients with Graves' disease in contrast to the earlier findings of Lennon et al. (1961). Hypermetabolism per se does not affect the acute T4* half-time. The administration of pharmacological doses of triiodothyronine, unlike similar doses of thyroxine, failed to affect the acute T4* half-time. The acute T4* half-time is consistently related in an inverse manner to the concentration of unsaturated thyroxine-binding sites in association with TBG. These data show no such correlation between TBPA binding and the acute T4 half-time. Synthetic oestrogen, by increasing the unsaturated thyroxine-binding capacity of TBG, produces a profound slowing of the acute T4* halftime.


Sign in / Sign up

Export Citation Format

Share Document